Aghajanian C et al. Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial. Gyn Oncol 2021;162(2):375-81. Abstract
Alvarez Secord A et al. PICCOLO: An open-label, single arm, phase 2 study of mirvetuximab soravtansine in recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate-alpha (FR-alpha) expression. SGO 2022;Abstract 300.
Banerjee et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2021;22(12):1721-31. Abstract
Colombo N et al. Overall survival data from a 3-arm, randomized, open-label, phase 2 study of relacorilant, a selective glucocorticoid receptor modulator, combined with nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer. ASCO 2022;Abstract LBA5503.
Cramer DW et al. Differential blood count as triage tool in evaluation of pelvic masses. Int J Gynecol Cancer 2021;31(5):733-43. Abstract
Dizon DS et al. Stage 1 results of BrUOG 354: A randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas (NCT03355976). ASCO 2022;Abstract 5598.
Drew Y et al. Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): Initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC). ESMO 2020;Abstract 814MO.
Drew Y et al. Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC). ESMO 2019;Abstract 4563.
Gonzalez-Martin A et al. Niraparib efficacy and safety in patients with BRCA-mutated (BRCAm) ovarian cancer: Results from three phase 3 niraparib trials. ASCO 2021;Abstract 5518.
Hardesty MM et al. Phase 2 OVARIO study of niraparib + bevacizumab therapy in advanced ovarian cancer following frontline platinum-based chemotherapy with bevacizumab. SGO 2022;Abstract 40.
Jang AI et al. Case report: Frontoparietal metastasis from a primary fallopian tube carcinoma. Front Surg 2021;8:594570. Abstract
Konstaninopoulos PA et al. Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol 2018;5(8):1141-9. Abstract
Kristeleit R et al. Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutant (ARIEL4): An international, open-label, randomised, phase 3 trial. Lancet Oncol 2022;23(4):465-78. Abstract
Li N et al. Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individual starting dose (PRIME study): A randomized, double-blind, placebo-controlled, phase 3 trial. SGO 2022;Abstract LBA5.
Liu JF et al. An open-label phase 2 study of dostarlimab, bevacizumab, and niraparib combination in patients with platinum-resistant ovarian cancer: Cohort A of the OPAL trial. SGO 2021;Abstract 10415.
Matulonis UA et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: Results from the SORAYA study. SGO 2022;Abstract LBA4.
Matulonis UA et al. Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase 3 trial of niraparib in recurrent ovarian cancer. SGO 2021;Abstract 11139.
Matulonis UA et al. Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FR-alpha) expression: Characterization of antitumor activity in the SORAYA study. ASCO 2022;Abstract 5512.
Monk BJ et al. A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). J Clin Oncol 2022;[Online ahead of print]. Abstract
Monk BJ et al. ATHENA (GOG-3020/ENGOT-ov45): A randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer. Int J Gynecol Cancer 2021;31(12):1589-94. Abstract
Monk BJ et al. ATHENA–MONO (GOG-3020/ENGOT-ov45): A randomized, double-blind, phase 3 trial evaluating rucaparib monotherapy versus placebo as maintenance treatment following response to first-line platinum-based chemotherapy in ovarian cancer. ASCO 2022;Abstract LBA5500.
Moore KN et al. A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. Future Oncol 2018:14(2);123-36. Abstract
Moore KN et al. Integrated safety summary of single-agent mirvetuximab soravtansine in patients with folate receptor alpha (FR-alpha)-positive recurrent ovarian cancer: Phase 1 and 3 clinical trials. ASCO 2022;Abstract 5574.
Moore KN et al. MIRASOL: A randomized, open-label, phase 3 study of mirvetuximab soravtansine vs investigator’s choice of chemotherapy in advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor alpha (FR-alpha) expression. SGO 2022;Abstract 297.
Nitecki R et al. Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials. Gynecol Oncol 2021;161(3):653-9. Abstract
O’Malley DM et al. Mirvetuximab soravtansine, a folate receptor alpha (FR-alpha)-targeting antibody drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer: Final analysis. ASCO 2021;Abstract 5504.
Porter R, Matulonis UA. Immunotherapy for ovarian cancer. Clin Adv Hematol Oncol 2022;20(4):240-53. Abstract
Porter RL et al. A phase 2, two-stage study of mirvetuximab soravtansine (IMGN853) in combination with pembrolizumab in patients with microsatellite stable (MSS) endometrial cancer (EC). ASCO 2021;Abstract TPS5611.
Poveda A et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): A final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2021;22(5):620-31. Abstract
Pujade-Lauraine E et al. Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): Phase IIIb OReO/ENGOT Ov-38 trial. ESMO 2022;Abstract LBA33.
Randall LM et al. MOONSTONE/GOG-3032: Interim analysis of a phase 2 study of niraparib + dostarlimab in patients (pts) with platinum-resistant ovarian cancer (PROC). ASCO 2022;Abstract 5573.
Richardson DL et al. Updated results from the phase 1b expansion study of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody drug conjugate (ADC) in ovarian cancer. SGO 2022;Abstract 76.
Selle F et al. OReO/ENGOT Ov-38 Trial: Impact of maintenance olaparib rechallenge according to ovarian cancer patient prognosis — An exploratory joint analysis of the BRCA and Non-BRCA Cohorts. ASCO 2022;Abstract 5558.
Wan C et al. Enhanced efficacy of simultaneous PD-1 and PD-L1 immune checkpoint blockade in high grade serous ovarian cancer. Cancer Res 2021;81(1):158-73. Abstract